Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 16/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 15/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317784 | 0.88 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9253766 | 0.88 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9656754 | 0.88 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL30463821 | 0.88 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9313643 | 0.88 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL20764447 | 0.87 | PTGS1 (0.62) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9688177 | 0.86 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15820661 | 0.85 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4319046 | 0.85 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL15819997 | 0.84 | PTGS1 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128523-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2021-05-06 | — | — | US | claimed |
| US-20200206235-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | SULFATEQ B.V. (NL) | 2020-07-02 | — | — | US | claimed |
| EP-3672593-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | Sulfateq B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| EP-3672592-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | Sulfateq B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038361-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| WO-2019038360-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | SULFATEQ B.V. (NL) | 2018-06-21 | — | — | US | claimed |
| EP-3297625-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | Sulfateq B.V. (NL) | 2018-03-28 | — | — | EP | claimed |
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | SULFATEQ B.V. (NL) | 2017-06-01 | — | — | US | claimed |
| EP-3157518-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | Sulfateq B.V. (NL) | 2017-04-26 | — | — | EP | claimed |
| WO-2016188766-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAMAGE | SULFATEQ B.V. (NL) | 2016-12-01 | — | — | WO | claimed |
| WO-2015193365-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | SULFATEQ B.V. (NL) | 2015-12-23 | — | — | WO | claimed |
| US-12156862-B2 | Medicaments for the treatment of vasoconstriction related diseases or disorders | SULFATEQ B.V. (NL) | 2024-12-03 | — | — | US | disclosed |
| US-11730741-B2 | 6-chromanol derivatives for use as a medicament | SULFATEQ B.V. (NL) | 2023-08-22 | — | — | US | disclosed |
| EP-3388426-B1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ BV (NL) | 2023-07-05 | — | — | EP | disclosed |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| WO-2015193365-A1 | 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-COMPOUNDS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASES | SULFATEQ B.V. (NL) | 2015-12-23 | — | — | WO | disclosed |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| EP-2935232-A1 | COMPOUNDS FOR PROTECTION OF CELLS | Sulfateq B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014098586-A1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151234-A1 | 6-Hydroxy-2,5,7,8-Tetramethylchroman-Compounds for the Treatment of Chronic Obstructive Airway Diseases | HRH4, CFTR, HRH2 | PTGS1 211/4885PTGS2 84/4885CYP1A2 361/4885 |
| US-20210227822-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | PTGS1 1184/4885PTGS2 1395/4885CYP1A2 3066/4885 |
| US-20150342174-A1 | COMPOUNDS FOR PROTECTION OF CELLS | CASP10, BAX, CASP9 | PTGS1 1184/4885PTGS2 1395/4885CYP1A2 3066/4885 |
| US-20180170892-A1 | COMPOUND FOR THE PROPHYLAXIS OR TREATMENT OF ORGAN DAGAMAGE | LIPG, GLS, TXN2 | PTGS1 75/4885PTGS2 109/4885CYP1A2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.